Back to top
more

Pliant Therapeutics (PLRX)

(Delayed Data from NSDQ)

$13.79 USD

13.79
322,966

0.00 (0.00%)

Updated May 7, 2024 04:00 PM ET

After-Market: $13.81 +0.02 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (74 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pliant Therapeutics, Inc. (PLRX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose

by Zacks Equity Research

Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.

How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 127%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Pliant Therapeutics, Inc. (PLRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study

by Zacks Equity Research

Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.

Sorrento (SRNE) Up on Positive Result From Lung Cancer Study

by Zacks Equity Research

Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.

bluebird (BLUE) Up 101% in the Past Three Months: Here's Why

by Zacks Equity Research

bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.

Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment

by Zacks Equity Research

Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.

How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 106%

by Zacks Equity Research

The mean of analysts' price targets for Pliant Therapeutics, Inc. (PLRX) points to a 105.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The Zacks Analyst Blog Highlights Absci Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics

by Zacks Equity Research

Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.

Kinjel Shah headshot

5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

by Kinjel Shah

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 0% and 269.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Amicus (FOLD) Q2 Earnings Beat, Galafold Sales Miss Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) posts a narrower-than-expected loss for the second quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics

by Zacks Equity Research

Amarin's (AMRN) Vazkepa sales decline year over year amid rising generic competition and COVID-related disruptions during the second quarter. The company's stock witnesses a decline on Aug 3.

Repligen (RGEN) Q2 Earnings and Sales Beat Estimates, Stock Up

by Zacks Equity Research

Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022

Analysts Estimate Kymera Therapeutics, Inc. (KYMR) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 142%

by Zacks Equity Research

The consensus price target hints at a 142.4% upside potential for Pliant Therapeutics, Inc. (PLRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Pliant Therapeutics (PLRX) Up on Positive Data From Lung Disease Study

by Zacks Equity Research

Pliant Therapeutics (PLRX) reports favorable data from a mid-stage study, which supports the potential of PLN-74809, its experimental drug candidate for treating IPF.

Pliant Therapeutics, Inc. (PLRX) Stock Jumps 159%: Will It Continue to Soar?

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -1.30% and 12.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -5.71% and 21.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 10.53% and 45.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Pliant Therapeutics, Inc. (PLRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Pliant Therapeutics, Inc. (PLRX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -5.63% and -35.60%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?